Quanterix brand Lucent Diagnostics released LucentAD Complete, a multi-analyte biomarker test from Lucent Diagnostics that detects p-Tau 217, Amyloid Beta (AB42/40 Ratio), Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP) in the blood to improve amyloid status classification and reduce the diagnostic gray zone by two-thirds.

Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.